Mobile

The primary objective of this study is to compare the analgesic efficacy and the safety of ABT-894 (6 mg tablets) administered twice daily (BID) to placebo in the treatment of diabetic neuropathic pai...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001140-47

The primary objective of this study is to compare the analgesic efficacy and the safety of ABT-894 (6 mg tablets) administered twice daily (BID) to placebo in the treatment of diabetic neuropathic pain (DNP).Additionally, this study will also explore the pharmacokinetic and pharmacogenetic characteristics of ABT-894 in the DNP population

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to compare the analgesic efficacy and the safety of ABT-894 (6 mg tablets) administered twice daily (BID) to placebo in the treatment of diabetic neuropathic pain (DNP).

Critère d'inclusion

  • Diabetic Neuropathic Pain

Liens